PATENT CLAIM ANALYSIS

Application Number: 16287413
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-08
Patent Classification: ["424", "482000"]

Abstract:
A method of treating a subject for a brain disease associated with cognitive impairment, including administering to a subject a chemical substance according to GLN-1062 or salt thereof: wherein the treatment includes transmucosal administration of a therapeutically effective amount of GLN 1062 or salt thereof in the oral cavity of the subject.

Claim (Index 16):
The method according to  claim 1 , wherein the brain disease to be treated is selected from the group consisting of Alzheimer's Disease, Parkinson's disease, dementia, schizophrenia, epilepsy, stroke, poliomyelitis, neuritis, myopathy, oxygen and nutrient deficiencies in the brain after hypoxia, anoxia, asphyxia, cardiac arrest, chronic fatigue syndrome, poisoning, anaesthesia, spinal cord disorders, central inflammatory disorders, postoperative delirium, subsyndronal postoperative delirium, neuropathic pain, abuse of alcohol or drugs, addictive alcohol craving, nicotine craving, and effects of radiotherapy.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 99.0
- Lexical Diversity: 1.375
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15699626', '13861134', '13213960', '11399879', '14189981']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7155028079020818
- 35 USC 102 Novelty (BERT): 0.4630888391090412
- Combined Prediction Score: 0.6902614110227777
- Mean Citation Score: 168.20383399999997
- Max Citation Score: 201.84703
- Similarity Product: 189.8996371015316

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test